[CAS NO. 71320-77-9] Moclobemide

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [71320-77-9]

Catalog

HY-B0534

Brand

MCE

CAS

71320-77-9

DESCRIPTION [71320-77-9]

Overview

MDL	MFCD00865388
Molecular Weight	268.74
Molecular Formula	C13H17ClN2O2
SMILES	O=C(NCCN1CCOCC1)C2=CC=C(Cl)C=C2

For research use only. We do not sell to patients.

Summary

Moclobemide (Ro111163) is a brain-penetrant and reversible monoamine oxidase ( MAO-A ) inhibitor with an IC ₅₀ of 6.061 μM for hMAO-A ^[1] .Moclobemide up-regulates proliferation of hippocampal progenitor cells in chronically stressed mice.

IC50 & Target

MAO-A

6.061 (IC ₅₀ )

In Vitro

NMDA (600 µM for 3 days) inhibits the proliferation of PC12 cells.Moclobemide (2 and 10 µM) up-regulates the proliferation in NMDA-treated PC12 cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis ^[2]

Cell Line:	PC12 cell line
Concentration:	Moclobemide (2 and 10 µM); N-methylaspartate (NMDA) (600 µM)
Incubation Time:	3 days
Result:	Treatment with NMDA significantly reduced the percentage of S-phase, while the percentage of other cell cycle phases did not change notablely.However,the percentage of S-phase increased in the presence of Moclobemide.

In Vivo

Moclobemide is a monoamine oxidase inhibitor and increases the levels of brain monoamines (such as 5-HT, norepinephrine).Moclobemide(40 mg/kg) is effective in animal behavior models ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Chronically stressed male mice (18±2 g) of the Kunming strain ^[2]
Dosage:	40 mg/kg
Administration:	I.p.; daily
Result:	BDNF level in the hippocampal subfields including subgranule zone decreased in stressed mice compared with normal control. Chronic treatment with Moclobemide could reverse these changes.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02374567	Hannover Medical School	Dementia\|Depression\|Schizophrenia\|Psychosomatic Disorders\|Anxiety Disorders	January 2015	Phase 3
NCT01926626	Jed E. Rose\|Philip Morris USA, Inc.\|National Institute on Drug Abuse (NIDA)\|Duke University	Nicotine Dependence	September 2013	Phase 2
NCT00534573	Beersheva Mental Health Center\|Tirat Carmel Mental Health Center	Clozapine-induced Hypersalivation	November 2008	Phase 3
NCT03010761	China Medical University Hospital	Addiction	January 14, 2016	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 372.11 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7211 mL	18.6053 mL	37.2107 mL
5 mM	0.7442 mL	3.7211 mL	7.4421 mL
10 mM	0.3721 mL	1.8605 mL	3.7211 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (9.30 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (9.30 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (9.30 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]-

4-Chloro-N-[2-(4-morpholinyl)ethyl]benzamide

Ro 11-1163

Moclobemide

4-Chloro-N-(2-morpholin-4-ylethyl)benzamide

Aurorix

4-Chloro-N-(2-morpholinoethyl)benzamide

Moclaime

Ro 11-1163/000

Manerix

p-Chloro-N-(2-morpholinoethyl)-benzamide

Auromid